Curis Inc income statement
In fiscal 2025, Curis Inc reported revenue of $9.4m, down 13.4% on the year before, operating income of −$5.7m (a -60.5% margin) and net income of −$7.6m, or −$0.58 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.
Income statement
| Fiscal year | 2009Dec 2009 | 2010Dec 2010 | 2011Dec 2011 | 2012Dec 2012 | 2013Dec 2013 | 2014Dec 2014 | 2015Dec 2015 | 2016Dec 2016 | 2017Dec 2017 | 2018Dec 2018 | 2019Dec 2019 | 2020Dec 2020 | 2021Dec 2021 | 2022Dec 2022 | 2023Dec 2023 | 2024Dec 2024 | 2025Dec 2025 | LTMJun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 9 | 16 | 15 | 17 | 15 | 10 | 8 | 8 | 10 | 10 | 10 | 11 | 11 | 10 | 10 | 11 | 9 | 4 |
| Research and development | 10 | 11 | 14 | 15 | 13 | 14 | 27 | 18 | 45 | 24 | 22 | 23 | 35 | 43 | 39 | 39 | 28 | 25 |
| General and administrative | 9 | 10 | 8 | 10 | 11 | 12 | 13 | 16 | 14 | 15 | 12 | 12 | 17 | 20 | 19 | 17 | 14 | 15 |
| Operating income | −10 | −6 | −7 | −19 | −9 | −16 | −56 | −58 | −50 | −29 | −24 | −25 | −42 | −53 | −48 | −45 | −6 | −9 |
| Interest expense | — | — | — | 0 | 4 | 4 | 3 | 3 | 4 | 4 | 1 | 0 | 0 | — | — | — | — | — |
| Income tax | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 0 | 0 | — |
| Net income | −10 | −4 | −10 | −16 | −12 | −19 | −59 | −60 | −53 | −33 | −32 | −30 | −45 | −57 | −47 | −43 | −8 | −21 |
| Diluted EPS | −$0.04 | −$1.50 | −$3.25 | −$5.25 | −$3.75 | −$5.50 | −$12.00 | −$2.25 | −$8.95 | −$4.90 | −$4.85 | −$3.05 | $5.00 | −$6.07 | −$4.48 | −$3.44 | −$0.58 | — |
| Diluted shares (average) | — | 3m | 3m | 3m | 3m | 3m | 5m | 5m | 6m | 7m | 7m | 10m | 9m | 9m | 11m | 13m | 13m | — |
| EBITDA | −9 | −5 | −7 | −18 | −9 | −16 | −56 | −58 | −50 | −29 | −24 | −25 | −42 | −53 | −48 | −44 | −6 | −9 |
| Quarter | 2024 Q3Sept 2024 | 2024 Q4Dec 2024 | 2025 Q1Mar 2025 | 2025 Q2Jun 2025 | 2025 Q3Sept 2025 | 2025 Q4Dec 2025 | 2026 Q1Mar 2026 | 2026 Q2Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 3 | 3 | 2 | 3 | 3 | 1 | 0 | 0 |
| Research and development | 10 | 9 | 9 | 7 | 6 | 6 | 6 | 7 |
| General and administrative | 4 | 3 | 4 | 4 | 4 | 3 | 5 | 3 |
| Operating income | −11 | −9 | −10 | −8 | −7 | 20 | −12 | −10 |
| Net income | −10 | −10 | −11 | −9 | −8 | 19 | −24 | −9 |
| Diluted EPS | −$1.70 | −$1.11 | −$1.25 | −$13.61 | −$9.80 | $1.61 | −$25.00 | −$4.02 |
| EBITDA | −11 | −9 | −10 | −8 | −7 | 20 | −12 | −10 |
Compare with peers
- Camp4 Therapeutics Corp income statement
- Ensysce Biosciences, Inc. income statement
- Ocugen, Inc. income statement
- Entrada Therapeutics, Inc. income statement
- Bolt Biotherapeutics, Inc. income statement
Head to head: CAMP vs CRISCRIS vs ENSCCRIS vs OCGN
More: Biotechnology stocks compared, Health Care sector, rankings of US companies